Author details

Full Name

Marcin Cieslik

Affiliation

ORCID

Career Start Year

2009

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37541199	Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.	Cell	2023
36350827	ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia.		2023
36382533	Differential responses to taxanes and PARP inhibitors in ATM-Â versus BRCA2-mutated metastatic castrate-resistant prostate cancer.	Prostate	2023
37597185	Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors.	Cell Rep	2023
38011559	Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy.	Proc Natl Acad Sci U S A	2023
37644036	Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.	Nat Commun	2023
36909546	Mass spectrometric profiling of HLA-B44 peptidomes provides evidence for tapasin-mediated tryptophan editing.	bioRxiv	2023
37085424	Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma.	Eur Urol	2023
37205448	Selective Enhancer Dependencies in -Intact and -Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma.		2023
36638784	Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy.	Cancer Cell	2023
36759899	Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.	Acta Neuropathol Commun	2023
37308510	Unraveling the glycosylated immunopeptidome with HLA-Glyco.	Nat Commun	2023
34363009	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.	Prostate Cancer Prostatic Dis	2022
35385733	Metabolism drives macrophage heterogeneity in the tumor microenvironment.	Cell Rep	2022
34840106	Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature.	Eur Urol Oncol	2022
35143422	Direct cellular reprogramming enables development of viral T antigen-driven Merkel cell carcinoma in mice.	J Clin Invest	2022
34644147	Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas.	Sci Transl Med	2021
33753452	Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer.	Clin Cancer Res	2021
33958760	LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy.	Nature Cell Biology	2021
33630025	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.	JAMA Oncol	2021
34099557	Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response.	Proc Natl Acad Sci U S A	2021
33513345	Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance.	Cancer Cell	2021
33550509	A novel ATXN1-DUX4 fusion expands the spectrum of 'CIC-rearranged sarcoma' of the CNS to include non-CIC alterations.	Acta Neuropathol	2021
33417831	Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma.	Cancer Cell	2021
33398162	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.	Nat Med	2021
34613815	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas.	Sci Transl Med	2021
32879489	Cancer SLC43A2 alters T cell methionine metabolism and histone methylation.	Nature	2020
32027624	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.	J Clin Invest	2020
32198885	Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element.	Nucleic Acids Res	2020
32025004	Global genomics project unravels cancer's complexity at unprecedented scale.	Nature	2020
31640893	Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.	Eur Urol	2020
32299640	Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms.	Eur Urol	2020
32154134	Mutations predictive of hyperactive Ras signaling correlate with inferior survival across high-risk pediatric acute leukemia.	Transl Pediatr	2020
31923397	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.	Cell	2020
31043744	CD8<sup>+</sup> T cells regulate tumour ferroptosis during cancer immunotherapy.	Nature	2019
31675502	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.	Cell	2019
31554642	Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11.	Cancer Discov	2019
31086175	PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.	Nat Commun	2019
30918020	Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer.	Clin Cancer Res	2019
30797188	Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma.	Neoplasia	2019
30735636	The Landscape of Circular RNA in Cancer.	Cell	2019
31061129	Genomic correlates of clinical outcome in advanced prostate cancer.	Proc Natl Acad Sci U S A	2019
31243372	Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.	Nature	2019
29808028	Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression.	Nat Genet	2018
32832832	Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors.	JCO Precis Oncol	2018
29980733	Competing for enhancers: PVT1 fine-tunes MYC expression.	Cell Res	2018
30340047	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.	Cell	2018
30382943	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.	J Clin Invest	2018
30285995	VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney.	Am J Surg Pathol	2018
29906450	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.	Cell	2018